US 7973045
Anhydrous form of dasatinib and process for preparation thereof
granted A61PA61P35/00A61P35/02
Quick answer
US patent 7973045 (Anhydrous form of dasatinib and process for preparation thereof) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Tue Jul 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P35/04, A61P43/00